TY - JOUR
T1 - Type 2 diabetes and cognitive dysfunction-towards effective management of both comorbidities
AU - Srikanth, Velandai
AU - Sinclair, Alan J
AU - Hill-Briggs, Felicia
AU - Moran, Chris
AU - Biessels, Geert Jan
N1 - Funding Information:
VS is supported by a Practitioner Fellowship from the National Health and Medical Research Council of Australia (1137837). GJB is supported by a Vici Grant (918.16.616) from the Netherlands Organisation for Scientific Research. GJB consults for and receives research support from Boehringer Ingelheim; all financial compensation for these services is transferred to his employer, UMC Utrecht. All other author declare no competing interests.
Publisher Copyright:
© 2020 Elsevier Ltd
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020/6
Y1 - 2020/6
N2 - Type 2 diabetes and cognitive dysfunction are highly prevalent disorders worldwide. Although type 2 diabetes is associated with an increased risk of dementia, awareness of the link between the two conditions is poor, and few recommendations are available to guide clinicians about how to approach cognitive dysfunction in people with diabetes. Clinical guidelines in diabetes have only recently begun to emphasise the importance of cognitive impairment in diabetes and its management. This Series paper aims to synthesise knowledge about the link between diabetes and cognitive dysfunction, issues pertaining to screening and diagnosis of cognitive impairment and dementia in those with type 2 diabetes, management of diabetes in people with cognitive dysfunction (accounting for age and frailty), and emerging therapies for prevention. A conceptual framework for approaching screening and diagnosis is included, and future research directions to guide the field forward are suggested.
AB - Type 2 diabetes and cognitive dysfunction are highly prevalent disorders worldwide. Although type 2 diabetes is associated with an increased risk of dementia, awareness of the link between the two conditions is poor, and few recommendations are available to guide clinicians about how to approach cognitive dysfunction in people with diabetes. Clinical guidelines in diabetes have only recently begun to emphasise the importance of cognitive impairment in diabetes and its management. This Series paper aims to synthesise knowledge about the link between diabetes and cognitive dysfunction, issues pertaining to screening and diagnosis of cognitive impairment and dementia in those with type 2 diabetes, management of diabetes in people with cognitive dysfunction (accounting for age and frailty), and emerging therapies for prevention. A conceptual framework for approaching screening and diagnosis is included, and future research directions to guide the field forward are suggested.
UR - http://www.scopus.com/inward/record.url?scp=85084740062&partnerID=8YFLogxK
U2 - 10.1016/S2213-8587(20)30118-2
DO - 10.1016/S2213-8587(20)30118-2
M3 - Review article
C2 - 32445740
SN - 2213-8587
VL - 8
SP - 535
EP - 545
JO - The Lancet Diabetes & Endocrinology
JF - The Lancet Diabetes & Endocrinology
IS - 6
ER -